For a period of 12 months all samples submitted for serum prolactin (PRL) assay and with PRL> 700 mUlL were examined by gel filtration chromatography. In 17 (25%) of 69 samples we found macroprolactin. The Delfia and Immuno I immunoassay systems gave similar PRL results with samples containing macroprolactin whereas the ACS 180 system gave lower results. With the De1fia and Immuno 1 systems samples containing substantial quantities of macroprolactin showed low recovery of PRL after precipitation with polyethylene glycol 6000 (PEG 6000) and this technique can be used as a screening test for macroprolactinaemia.
Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol
M N Fahie-Wilson and S G Soule I From the Department of Clinical Chemistry, Southend Hospital, Westcliff-on-Sea, Essex SSD DRY and lEndocrine Unit, University College London Medical School, London WIN 8AA, England SUMMARY. For a period of 12 months all samples submitted for serum prolactin (PRL) assay and with PRL> 700 mUlL were examined by gel filtration chromatography. In 17 (25%) of 69 samples we found macroprolactin. The Delfia and Immuno I immunoassay systems gave similar PRL results with samples containing macroprolactin whereas the ACS 180 system gave lower results. With the De1fia and Immuno 1 systems samples containing substantial quantities of macroprolactin showed low recovery of PRL after precipitation with polyethylene glycol 6000 (PEG 6000) and this technique can be used as a screening test for macroprolactinaemia.
We conclude that macroprolactinaemia is a common phenomenon and, in assays which detect this species, is a common cause of hyperprolactinaemia. Macroprolactinaemia may contribute to the difficulty in establishing an upper limit of the reference range for serum PRL. In our experience, patients with macroprolactinaemia do not exhibit features of the hyperprolactinaemia syndrome and it is important to recognize macroprolactin as the cause of hyperprolactinaemia to avoid unnecessary investigation and treatment.
Additional key phrases: serum prolactin; gel filtration; immunoassay Prolactin (PRL) in human serum exists in multiple molecular forms with three species identified by gel filtration chromatography (GFC); monomeric PRL (MW 23 kD), big PRL (MW 50--60kD) and big-big PRL (macroprolactin, MW 150--170kD).l Recent studies>" have focused on macroprolactin and indicate that this is a complex ofPRL with an IgG antibody which is variably reactive in immunoassay for PRL. It is speculated that the plasma half-life of the IgG PRL complex is prolonged, leading to apparent hyperprclactinaemia." The bioactivity of macroprolactin remains contentious; in vitro studies using an Nb2lymphoma cell line have suggested both preserved and reduced bioactivity;' 6 while patients with macroprolactinaemia have variable evidence of the hyperprolactinaemia syndrome (galactorrhoea, menstrual disturbance and infertility in women and impotence with loss of libido in men).3.6-R Correspondence: Mr MN Fahie-Wilson.
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The prevalence and clinical impact of macroprolactinaemia in general endocrinologicalor gynaecological practice is unknown.! although it may be a common phenomenon which is important to identify to avoid unnecessary investigation and treatment. The paucity of information regarding prevalence may be partly due to the fact that GFC is a time consuming and expensive technique for the identification of macroprolactin; a simpler test is required.? Polyethylene glycol (PEG) has been successfully employed to assist second antibody precipitation in radioimmunoassays and to precipitate [ 1251] PRL antibody complexes." It has been suggested that precipitation with PEG might form the basis of a screening test for rnacroprolactinaemia.!
In this study we sought to evaluate both the prevalence and clinical significance of macroprolactinaemia in all hyperprolactinaemic samples received in a district general hospital laboratory. Over 12 months from July 1994 all samples submitted for PRL assay with an elevated total serum PRL (> 700 m U/L) were examined for macroprolactin by GFC to determine the prevalence of this condition. We also studied the response of serum PRL to precipitation with PEG and evaluated the potential of this technique as a screening test for macroprolactinaemia. Finally, the case records of the subjects with macroprolactinaemia were retrospectively reviewed to determine the clinical impact of this phenomenon.
METHODS
Macroprolactin was identified by gel filtration chromatography on Sephacryl S-300 (Pharmacia) as a peak of immunoreactive prolactin eluting between IgA and IgG. One millilitre serum was applied to a column, diameter 1·5cm and height 50ern, and eluted with 10rnrnol/L tris buffer pH 7·40 containing 140mmol/L sodium chloride, 1·25mmol/L calcium chloride and 0·50mmol/L magnesium chloride, flow rate O'5 mL/min. 9 The first 30 mL of eluent was discarded and thereafter 40 fractions of approximately 1mL were collected. Fractions nearest 43·5 (fraction I) and 55·5 mL (fraction 2) were analysed for prolactin by fluoroimmunoassay (Auto Delfia, Wallac, UK). If prolactin was detected in fraction I, indicating the presence of macroprolactin, all 40 fractions were analysed to confirm the presence of two peaks of prolactin immunoreactivity and macroprolactin was quantitated from peak area. For all samples, 10 fractions between 43·5 and 55·5mL were analysed for albumin (BCG) and the position of the albumin peak was used to monitor the performance of chromatography.
In experiments with polyethylene glycol molecular weight 6000 (PEG 6000), 200 J-LL serum was mixed with an equal volume of a solution of PEG 6000 and, after thorough mixing, was centrifuged at 3000 rpm for 30min. Immunoreactive prolactin was measured in the supernatant without delay and the results were compared with those obtained from a one in two dilution of unprecipated serum in GFC buffer and expressed as PRL recovery (%). Using this technique we studied the effects of PEG concentration and of temperature on the precipitation of PRL from serum containing monomeric PRL and macroprolactin.
Unless stated otherwise PRL was measured in serum, fractions from GFC and in the supernatant after PEG precipitation of serum using a sandwich, solid phase fluoroimmunoassay (Auto Macroprolactinaemia 253
Delfia). The limit of detection of this assay was I· 5 m U/L, the intra assay coefficient of variation (CV) was 3% and interassay CV 2%. Sera containing macroprolactin were also assayed for PRL using two other commercially available automated immunoassay systems; a sandwich, enzyme-labelled assay with magnetic separation (Technicon Immuno 1, Miles, UK) and a sandwich, chemiluminescent assay with magnetic separation (ACS 180, CIBA-Corning, Halstead, UK).
RESULTS
Southend Hospital serves a local population of 325000. In a 12 month period from mid-July 1994, we received 1079 requests for serum PRL assay from 955 different patients and 71 patients (7'4%) had PRL >700mU/L. The major sources of the requests were as follows; general practitioners 56%, gynaecologists 23%, endocrinologists 11%.
Gel filtration
Sera from 69 of the 71 patients with PRL >700mU/L were examined by gel filtration. Figure I shows representative results of gel filtration chromatography of serum containing both macroprolactin and monomeric prolactin compared with serum containing only the latter species. In 52 (75%) of the samples examined, immunoreactive PRL in fraction 1 was < 3% of that in fraction 2 from the monomeric peak. The remaining 17 (25%) samples showed substantial immunoreactive PRL in fraction 1 (8-90%). The presence of macroprolactin in these samples was confirmed by analysis of all 40 fractions and quantitated from the area under the peak. Clinical data relating to these subjects are shown in Table I .
PEG precipitation
In experiments with PEG precipitation the following results were obtained:
Prolactin recovery after PEG precipitation decreased with increasing PEG concentration ( Fig. 2 ). On increasing PEG concentration from 150-300 g/L, recovery in samples containing no macroprolactin decreased by 20%, whereas in samples containing 70-90% macroprolactin recovery decreased by 5%. Precipitation of macroprolactin appeared to be maximal at a PEG concentration of 250 g/ L and this was used in the following experiments.
2 Prolactin recovery after PEG precipitation (250 giL PEG) was temperature dependent for samples containing monomeric PRL and those containing macroprolactin. Increasing the temperature at which precipitation and centrifugation were conducted from 10-30"C increased PRL recovery by 16-19% in serum containing only monomeric PRL and by 2-6% in serum containing macroprolactin ( Fig. 3 ). 3 Repeated assay on seven occasions over 6 weeks of PRL recovery after PEG precipitation (250 giL PEG) using frozen serum containing 83% macroprolactin showed mean recovery of 9·5% (SD 0,6) and in serum containing no macroprolactin, 77,6%, (SD 4'5). 4 Over a period of 6 months with no change of reagent, mean recovery of PRL after PEG precipitation (250 giL PEG) of serum containing only monomeric PRL decreased from 82% to 58%. Recovery improved on preparation of fresh PEG reagent, although no reason for the decline in recovery has been found. We recommend that the PEG reagent is prepared freshly every 3 months. 5 45 samples with no evidence of macroprolactin on GFC were precipitated with PEG 250 giL at room temperature and recovery of immunoreactive PRL in the supernatant was 44-96%, while in the 17 samples containing macroprolactin recovery was 11-81 %. The overlap encompassed only one sample containing 8% macroprolactin and all 16 samples containing substantial quantities of macroprolactin as detected by GFC were distinguishable from samples containing only monomeric PRL by the low recovery (:::;40%) of immunoreactive PRL after precipitation with PEG ( Fig. 4 ). Figures 5 and 6 show comparisons of the Immuno I and the ACS 180 assays with the Delfia technique using sera containing macroprolactin or only monomeric prolactin. The Delfia assay gave higher results than the Immuno I assay and the bias was not influenced by the presence of macroprolactin. With II sera containing only monomeric PRL, results from the Delfia assay were on average 11·0% higher (range 4,2-28·4%) and with 13 sera containing macroprolactin, 9·3% higher (104-24'0%).
Comparison of immunoassays
The Delfia assay also gave higher results than the ACS 180 assay but the presence of macroprolactin had a marked influence on the bias. With 10 sera containing only monomeric PRL results from the Delfia assay were on average 2204% higher (-1·6-3104). Taking the upper limit of normal 700mUjL used to define hyperprolactinaemia in this study and adjusting for this method bias gives an equivalent limit of 550 mUj L for the ACS 180 assay. With 12 sera containing macroprolactin the Delfia assay gave results on average 95·8% higher (35'5-159'9) than the ACS 180 assay. In these samples PRL measured by Delfia was 696-2880mUjL and by ACS 180 149-1156, with only two results above 550 m UjL.
PEG precipitation appears to cause positive interference in the Irnmuno 1 assay giving a recovery of greater than 100% with the assay standard ( Table 2 ). Recovery of PRL in sera containing only monomeric PRL was higher than with the Delfia assay and also occasionally greater than 100%. Nevertheless, recovery of PRL from sera containing macroprolactin was characteristically lower. Finally, a recent evaluation'? of the prevalence of macroprolactinaemia in 60S sera with total PRL> 1000 mUlL reported findings remarkably similar to our own-26% had an increase in ISG-170kD PRL.
The clinical impact of macroprolactinaemia remains controversial, with some reports documenting associated galactorrhoea and menstrual disturbance, while others suggest that patients In contrast, PEG causes negative interference with the ACS 180 assay. Recovery ofPRL from the ACS 180 assay standard and from sera containing only monomeric PRL after PEG precipitation was lower than with the Delfia and Immuno I assays. Recovery of PRL from sera containing macroprolactin was lower than from sera containing only monomeric PRL but the difference was less than with the Delfia and Immuno I assays.
DISCUSSION
The occasional presence of macroprolactin in human serum has, for many years, been identified by GFC,IO.ll although only recently has it been shown to behave as immunoglobulin bound PRL.3,4 Macroprolactinaemia and antiprolactin autoantibodies have been reported frequently in patients with idiopathic hyperprolactinaemia'rt-P and our finding of macroprolactin in many patients with hyper-prolactinaemia is not unprecedented. Soong et al. 14 (1982) may remain asymptomatic despite marked macroprolactinacmia.V' H. 12 The notion that a high molecular weight prolactin-immuno-globulin complex may have a reduced capacity to cross vascular endothelium and thus limited bioactivity is attractive? and finds some support from our clinical data (Table I) . None of the subjects with macroprolactinaemia presented with menstrual disturbance which could not be accounted for by polycystic ovaries, and galactorrhoea was not a feature of the clinical presentation. Nevertheless, it is interesting to note that the calculated monomeric PRL concentration remained > 700 mUjL in three patients. In the six patients in whom pituitary imaging was performed, we were unable to document a pituitary adenoma. Although it would be premature to make firm recommendations on the limited data available, it may be that the detection of substantial macroprolactin-aemia with a normal calculated monomeric PRL concentration obviates the need for pituitary imaging. In defining hyperprolactinaemia we have used 700 mUjL as the upper limit of the normal reference range as suggested by Jeffcoate et al."
The distribution of serum PRL concentrations in the normal population is skewed towards higher values making a normal reference range difficult to define and resulting in considerable variation in the normal ranges used by different laboratories.!' We found macroprolactin in 13 of 44 (30%) subjects with total serum PRL between 700 and 1500 m UjL and the calculated monomeric PRL concentration in II of these (85%) was less than 700mUjL. It therefore seems probable that macroprolactinaemia is a major contribution to the skewed distribution of total serum PRL and that monomeric serum PRL may show a distribution more nearly Gaussian. Analysis of a larger number of macroprolactin samples would be required to further explore this hypothesis.
Our comparison of different immunoassays confirms and extends the observations of Bjaro et al. ' ? in demonstrating that macroprolactin is variably reactive in assay systems. The Delfia and Immuno I assays appear to recognize monomeric and macroprolactin similarly and macroprolactinaemia can be identified in both assays with the PEG precipitation technique. The ACS 180 assay appears to react largely with monomeric PRL but there is some contribution from macroprolactin and precipitation with PEG may identify this. Clearly, the specificity of the immunoassay employed will have a marked effect on the apparent prevalence of hyperprolactinaemia due to macroprolactin-aemia.
It seems probable that macroprolactinaemia has been inadequately evaluated in the past because of the lack of a simple method for identifying this species. Precipitation with PEG is a classic technique for fractionation of protein mixtures and has been employed to assist second antibody precipitation in the radioimmunoassays and to precipitate [! 2S I] PRL-antibody complexes.' The technique has also been used to identify macroamylase," a complex of amylase with IgG or IgA analogous to macroprolactin.l? Precipitation of macroprolactin in serum with PEG is neither specific nor quantitative but in our study all 16 samples containing substantial quantities of macroprolactin were distinguished from samples containing only monomeric PRL by the low recovery «40%) of immunoreactive PRL after precipitation with PEG. We suggest that PEG precipitation of macroprolactin may provide a simple and effective screening method for macroprolactin.
In conclusion, our study provides a comprehensive assessment of macroprolactin as a cause of hyperprolactinaemia in general practice. We would emphasize the view of Lindstedt-that macroprolactinaemia is a common phenomenon which should be sought for by all laboratories offering a prolactin assay service and using an assay which detects macroprolactin. Furthermore, we have shown that precipitation with PEG provides a simple screening method for the detection of macroprolactin. Finally, patients with macroprolactinaemia do not in our experience manifest features of the hyperprolactinaemic syndrome.
